Maternal Serum Screen Flashcards

1
Q

What is a Screening Test?

-it is a ____ ________, and not a diagnostic test

-the result is a ________, and not a certainty
——-_________= higher likelihood/ risk of the disease
——-________=lower likelihood/ risk of the disease

The screening procedure itself does not diagnose the illness

A

risk assessment

likelihood

Positive
Negative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

____________

-Identification, from among apparently healthy individuals, of those sufficiently at risk of a specific disorder to justify a subsequent diagnostic test or procedure

-Screen with a less-invasive test: followed by a more invasive test to confirm diagnosis

A

Screening

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is sensitivity and specificity?

Sensitivity and specificity are measures of a test’s ability to correctly classify a person as having a disease or not having a disease.

___________-is the ability to assign an individual with the disease as positive. A highly sensitive test means that there are few false _________ results, and thus fewer cases of disease are missed.

__________- is the ability to assign an individual who does not have the disease as negative. A highly specific test means that there are few false ________ results.

A

Sensitivity
Negative

Specifity
Positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Criteria for Screening (True or False)

-you don’t screen for diseases that are not severe or diseases of high incidence

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Criteria for Screening (True or False)

-disorder should be well-defined, with known prevalence

-severity of disease (high) vs. prevalence (low)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Criteria for Screening (True or False)

-disorder should represent a substantial public health burden

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Criteria for Screening (True or False)

-there may not be an effective remedy for the disorder

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Criteria for Screening (True or False)

-tests should be simple, safe, stable

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Criteria for Screening (True or False)

-cost effective: cost of health care (high) vs. cost of screen (low)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Criteria for Screening (True or False)

-Ethical: follow-up diagnostic procedures in place

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Criteria for Screening (True or False)

-made available to the most of population

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Criteria for Screening (True or False)

-distribution of test values in affected populations is known

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Criteria for Screening (True or False)

-degree of overlap with unaffected populations is small, and the cut-off (or decision point) is defined

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Criteria for Screening (True or False)

-follow up testing: risk of miscarriage, use of therapeutic abortion is an ethical issue, parent’s choice in Canada

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Limitations of Screening Tests (1 of 3)

1.Cut off values for populations of unaffected & affected overlap
—–screening “cut off” point used to determine negative and positive values refer to marker concentrations

  1. False negative: below the cut-off there is a segment of the affected population who will be screen-negative.

3.False positive: above the cut-off there is a segment of the unaffected population who will be screen-positive

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Limitations of Screening Tests (2 of 3)

  1. detection rate (Sensitivity)
    ——-the fraction of the affected population that is screen positive
  2. false positive rate (Specificity)
    ——the fraction of the unaffected population that is screen positive

Note: No screening tests have a 100% detection rate; all screening tests have some false positives.
Ideally?
Sensitivity = detection rate = does the screen detect ALL those affected?

Specificity vs. false positive rate = does it detect ONLY those who are affected?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Limitations of Screening Tests (3 of 3)

  1. Can we change the screening cut-off?
    —–Increase cut off:
    decrease false positive rate, decrease detection rate

—–decrease cut off:
increase detection rate, increase false positive rate

Must have a huge amount of data before changing cut-off!

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

__________ screening:

To determine the likelihood the baby may havetrisomy 21 (Down syndrome)ortrisomy 18.

Anyone may have a pregnancy with trisomy 21 or trisomy 18, regardless of their family history.

-This chance increases with the age of the mother or the age of egg donor.

-Prenatal screening poses little risk to the pregnancy as it involves ultrasound and blood work.

—–enhanced first trimester screening(eFTS)

—–maternal serum screening(MSS)

—–Non-invasive prenatal testing(NIPT)

A

Pre-natal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

__________ _________ Screen

-Testing the serum of the mother

-goal is to identify fetus at risk for a specific disorder

-blood test for certain biochemical markers is a good preliminary test

A

Maternal Serum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

_______ ________ _________(NSO)

-screens newborn blood spot samples for groups of diseases.

A

Newborn Screening Ontario

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Newborn Screening Ontario

__________ Diseases - where the body is unable to break down certain substances in foods, like fats, proteins or sugars

A

Metabolic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Newborn Screening Ontario

__________ Diseases - where the body produces too much or too little of certain hormones

A

Endocrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Newborn Screening Ontario

________ _________ Disease (SCD) - which affects the movement of oxygen in the blood

A

Sickle Cell Disease

24
Q

Newborn Screening Ontario

_________ ________ - which causes problems with breathing and growth

A

Cystic Fibrosis

25
Newborn Screening Ontario ________ __________ ________ _________(SCID) - which affects the body’s ability to fight infections
Severe Combined Immune Defficiency
26
Newborn Screening Ontario ________ __________ _________ (SMA) - which causes muscle weakness and wasting
Spinal Muscular Atrophy
27
Newborn Screening Ontario ______ _________ ________ ________ (CCHD) - which affects the quantity of oxygen in the blood.
Critical Congenital Heart Disease
28
Newborn Screening Ontario (NSO) Specimen: small blood sample if place on a paper slide. About 3-5 drops of baby’s blood is needed for all these tests Tandem Mass Spectrometry (flow-injection): ----Amino acidopathies (i.e. phenylalanine, tyrosine etc.) ---Organic acidopathies and fatty acid oxidation defects (i.e. C3, C8, C14:1, acylcarnitines etc.) Tandem Mass Spectrometry (LC-MSMS): ---Congenital adrenal hyperplasia (2nd tier steroid profile) ---Organic acidopathies (2nd tier methylcitrate assay) Immunoassay: ---Congenital adrenal hyperplasia (17OHP) ---Congenital hypothyroidism (TSH) ---Cystic Fibrosis (IRT) Enzymatic assays: ---Biotinidase ---Galactosemia HPLC: ---Hemoglobinopathies DNA: ---Severe Combined Immunodeficiency
29
_______ _________ _________ (NTDs) -all or part of the neural tube fails to close completely during fetal development. -defects of spinal cord & brain derived from a structure in the developing embryo called the neural tube -Canadian incidence: 1/2000 births (does not vary with maternal age)
Neural Tube Defects
30
Neural Tube Defects (NTDs) open defect (most common) _______ ______: failure of spinal cord to close ___________: failure of skull to close, and neural tissue left exposed _______ defect --defect covered with bone & skin --less impairment
Spina bifida Anencephaly Closed
31
________ ________ Pathophysiology: --paralysis of lower limbs --loss of motor control of bladder, bowels --hydrocephalus (water on brain) --mental disabilities (variable)
Spina Bifida
32
Spina Bifida ______________: the spinal cord is involved & protrudes from a hole in the bone of the spine ____________: the spinal cord does not leave the protective bone tube (less severe)
Myelomeningocele Meningocele
33
___________ Complete or partial absence of the cranial vault, the forebrain, the midbrain, membranes & skin & possibly spinal cord newborns with severe form die shortly after birth
Anancephaly
34
NTDs cont’d exact cause of NTDs is not clear: -__________ component -----family history, previous affected birth -----likely a genetic mutation: folic acid may prevent a genetic mutation -__________ component -----higher frequency in Caucasians of Celtic Irish, Scots and Welsh descent -_________ component -----daily intake of folic acid one month before conception & during pregnancy has been shown to reduce the risk
genetic ethnicity dietary
35
How do we detect NTDs? -fetal proteins leak into amniotic fluid -proteins enter maternal circulation by transfer & diffusion across placental membranes -alpha-fetoprotein (AFP) detectable in both amniotic fluid & maternal serum -open NTDs: levels of AFP are increased in both amniotic fluid & maternal serum
36
_______ __________ -the first marker used for MSS -protein: MW 70kDa, 591 aa -synthesized initially by fetal yolk sac & later by fetal hepatocytes -elevated amniotic fluid AFP concentration crosses the placenta, and leads to increased amounts in the maternal blood -fetal blood levels peak 10-13 weeks gestation & then decline until term -maternal serum levels peak at 28-32 weeks gestation, & then decline until term
Alpha-fetoprotein
37
Analysis of Maternal Serum AFP (MSAFP) Maternal blood at __-___ weeks gestation
16-20
38
MSS Markers: Reporting & Interpretation MSS Markers are reported in units called ____________ ___ ___ __________ (MoM) -units correlate to the risk of NTDs -units more reliable & allow for inter-laboratory variation / comparisons -it is the maternal serum marker conc’n (ug/L) median reference for serum marker for gestational age -increased AFP MoM levels above the cut-off indicate presence of NTD -Correction factors used to account for maternal age, race, weight, gestational age, level of nutrition, diabetes
Multiples of the Median
39
Interpretation of MSAFP Results -MSAFP cut-off is ___ - ___ MoM -levels above the cut-off is a _____ screen and require further investigation -MSAFP detects most NTDs: ----open spina bifida ___-___% of cases ----anancephaly > ___% cases -follow up testing more invasive, but more conclusive
2.0-2.5 positive 70-80 90
40
Follow-up Testing for Screen Positive MSAFP
41
_____________ -ultrasound used to guide needle -collect ~20 mL -risk: up to 0.5% (1:200) spontaneous miscarriage -measure AFP, AchE
Amniocentesis
42
________ _________ (_______ __) -extra copy of long-arm of chromosome 21 -mental retardation, low muscle tone, congenital heart defects, flat facial profile, larger protruding tongue -incidence increases with maternal age: 1:1300 age 25, 1:365 age 35, 1:100 age 40, 1:30 age 45 -maternal age alone is a screening test -most common serious disorder resulting from a chromosomal abnormality in live born babies -A correlation between decreased MSAFP levels & DS first identified in 1984 -decreased maternal serum AFP levels < 0.5 MoM are suggestive of DS Problem: too much overlap
Down syndrome (Trisomy 21)
43
Down Syndrome (Trisomy 21) Confirmation test: ________ chromosome Cytogenetics analysis -----amniocentesis (___-___ wks) -----chorionic villus sampling (CVS) (__-___ wks) -----percutaneous umbilical cord blood sampling (PUBS) (__-___ wks): high risk _____- contains fetal cells from chorion that is placental tissue derived from fetal side of placenta ______-needle guided by Ultrasound through abdomen & uterine wall to umbilical cord: small sample of fetal blood obtained for testing
Karyotyping 15-20 weeks 10-13 weeks 18-20 weeks CVS PUBS
44
________ ________ Screen -3 markers in maternal serum measured by immunoassay during 2nd trimester: AFP, hCG, uE3 -Screens for NTDs and Down Syndrome -test offered to all pregnant women in Ontario regardless of their age -one blood sample taken at 16-18 wks An ________ levels of hCG and ________ levels of unconjugated estriol (uE3) associated with Down Syndrome
Triple Marker increased; decreased
45
______ __________ ______________ -maternal serum marker for detection of fetus with Down syndrome, but not NTD -hCG MoM of 2.5 or higher associated with DS -only detects 40% of DS pregnancies if used alone (poor sensitivity if used alone)
Human Chorionic Gonadotropin
46
________ ________ -early in second trimester, fetus begins to synthesize large amounts ------a complex series of enzymatic reactions involving fetal liver, fetal adrenal glands, & placenta ----rises progressively throughout gestation ----A decreased level in maternal serum is a predictor of DS & NTD
Unconjugated Estriol
47
Interpretation: Triple Marker Screen suspected NTDs 1. refer to Genetics 2. Level II ultrasound 3. amniocentesis: analyze amniotic fluid AFP & acetylcholinesterase suspected DS 1.refer to Genetics 2.Ultrasound 3.confirm with karyotyping (amniocentesis, CVS, PUBS, )
48
Laboratory Considerations
49
Calculating Risk & Reporting A “screen positive” result means fetus has an increased chance of having one of the screened conditions Confirmation testing may conclude that baby does not have one of the conditions (i.e., false positive rate or specificity of the screen) A “screen negative” result means chance for having a baby with the condition screened for is lower than the standard screening cut-off and is not considered to be at an increased risk does not guarantee birth of a baby without problem for every pregnancy, there is a 2-3% chance for having a baby with some problems at birth
50
Quad Screen- Dimeric Inhibin A (DIA) -Ontario’s screening programs have added 4th serum marker: -_________- are glycoprotein hormones secreted by ovaries in non-pregnant women, and by the placenta -In a non-pregnant state, it suppresses the secretion of FSH --------function in pregnancy is unknown -levels ________ in both NTD and DS --------measurement of additional markers has been shown to increase detection rate & decrease false positive rates
inhibin increased
51
_______ _________ _________ Performed at 11-14 wks gestation (earlier than triple screen), measurement of 2 serum markers AND Ultrasound: 1. free-beta subunit hCG (in serum: is not protein bound) -----------__________ in DS 2. pregnancy associated plasma protein A (PAPP-A) ----------___________ in DS 3. includes a fetal ultrasound: nuchal translucency (NT) ------------NT __________ with DS and some other birth defects
First Trimester Screening 1.increased 2. decreased 3. increased
52
_________ ____________ -measure fluid accumulation at the back of the fetal neck (nuchal region between back of spine and skin) -measurements greater than 3.0 mm need further investigation (usually no greater than 1 or 2 mm thick)
Nuchal Translucency
53
First Trimester Screening
54
More Recent Screening
55
Trisomy 18
56
cell free- DNA
57
Review Questions